DOLORES REXACH: Open Payments
NPI 1386987626 · DORAL, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$833 in 38 payments from 11 companies in 2025. Trend: 2023 $1,023 · 2024 $1,695 · 2025 $833
Food & beverage: $833
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $271 |
| Vanda Pharmaceuticals Inc. | 4 | $96 |
| Axsome Therapeutics, Inc. | 3 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 3 | $67 |
| Corium, LLC | 4 | $60 |
| E.R. Squibb & Sons, L.L.C. | 2 | $50 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
Products named: VRAYLAR, Auvelity, CAPLYTA, SPRAVATO, REXULTI, Azstarys, HETLIOZ, COBENFY.
Industry payments across FL — which companies pay providers there.
